Eli Lilly (LLY) Reports IMC-1121B Met Primary Endpoint in Phase III
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Leerink Swann Upgrades Eli Lilly (LLY) to Outperform Following Solid Ramucirumab New
October 15, 2012 11:28 AM EDTLeerink Swann upgraded Eli Lilly (NYSE: LLY) from Market Perform to Outperform and raised its price target from $52 to $59-$60 following positive Ramucirumab... More
